Documents

Obesity drug focus shifts to metabolic health, with flexible dosing and strong pipeline momentum.

Major ADA data for petrelintide and survodutide, with strong R&D and financial momentum.

Strong clinical progress and robust financials drive confidence and capital return in 2026.

Late-stage obesity and rare disease assets drive growth, backed by strong partnerships and cash.

Petrelintide and Survodutide advance as key assets, with major clinical milestones expected this year.

Petrelintide showed robust weight loss and exceptional tolerability in phase II, supporting phase III advancement.

Major clinical data for petrelintide and Survodutide will define a transformative year in metabolic health.

Record 2025 profit and cash enable accelerated obesity pipeline progress and major 2026 milestones.

Petrelintide and Survodutide anchor a bold strategy to lead metabolic health innovation by 2030.

Petrelintide targets a new obesity therapy category, emphasizing efficacy, tolerability, and growth.

Obesity pipeline advances, Roche deal boosts cash, and focus shifts to high-impact R&D assets.

Petrelintide advances in late-stage trials, targeting obesity with strong efficacy and tolerability.

Differentiated obesity therapies, strategic Roche partnership, and major clinical milestones ahead.

H1 2025 revenue surged to DKK 9.1B, obesity pipeline advances, and cash position strengthened.

Petrelintide advances with Roche partnership, targeting durable obesity solutions and market leadership.

Transformative Roche partnership and robust pipeline position for leadership in obesity therapeutics.

Strong R&D investment and Roche deal position Zealand Pharma for growth in obesity therapeutics.